NAMS
Price
$27.87
Change
+$0.09 (+0.32%)
Updated
Aug 21 closing price
Capitalization
3.33B
80 days until earnings call
Intraday BUY SELL Signals
TRVI
Price
$17.96
Change
-$0.29 (-1.59%)
Updated
Aug 21 closing price
Capitalization
2.56B
80 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAMS vs TRVI

NAMS vs TRVI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NAMS vs. TRVI commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Hold and TRVI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (NAMS: $27.87 vs. TRVI: $17.96)
Brand notoriety: NAMS and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 37% vs. TRVI: 39%
Market capitalization -- NAMS: $3.33B vs. TRVI: $2.56B
NAMS [@Biotechnology] is valued at $3.33B. TRVI’s [@Biotechnology] market capitalization is $2.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileTRVI’s FA Score has 1 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • TRVI’s FA Score: 1 green, 4 red.
According to our system of comparison, TRVI is a better buy in the long-term than NAMS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 3 TA indicator(s) are bullish while TRVI’s TA Score has 2 bullish TA indicator(s).

  • NAMS’s TA Score: 3 bullish, 5 bearish.
  • TRVI’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, TRVI is a better buy in the short-term than NAMS.

Price Growth

NAMS (@Biotechnology) experienced а +3.30% price change this week, while TRVI (@Biotechnology) price change was -2.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

NAMS is expected to report earnings on Nov 11, 2026.

TRVI is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($3.33B) has a higher market cap than TRVI($2.56B). TRVI YTD gains are higher at: 43.450 vs. NAMS (-20.553). TRVI has higher annual earnings (EBITDA): -46.12M vs. NAMS (-214.95M). NAMS has more cash in the bank: 636M vs. TRVI (172M). NAMS has less debt than TRVI: NAMS (23K) vs TRVI (682K). NAMS has higher revenues than TRVI: NAMS (22.6M) vs TRVI (0).
NAMSTRVINAMS / TRVI
Capitalization3.33B2.56B130%
EBITDA-214.95M-46.12M466%
Gain YTD-20.55343.450-47%
P/E RatioN/AN/A-
Revenue22.6M0-
Total Cash636M172M370%
Total Debt23K682K3%
FUNDAMENTALS RATINGS
TRVI: Fundamental Ratings
TRVI
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
PROFIT vs RISK RATING
1..100
5
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NAMSTRVI
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 3 days ago
69%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 21 days ago
77%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NAMS
Daily Signal:
Gain/Loss:
TRVI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CSM88.600.41
+0.46%
ProShares Large Cap Core Plus
ERY9.020.04
+0.45%
Direxion Daily Energy Bear 2X ETF
NXUS24.64N/A
N/A
Nuveen International Aggregate Bond ETF
TAIL10.31-0.04
-0.43%
Cambria Tail Risk ETF
PYPU43.25-1.19
-2.69%
Direxion Daily PYPL Bull 2X Shares

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+0.32%
PTGX - NAMS
43%
Loosely correlated
+2.41%
IMVT - NAMS
42%
Loosely correlated
+0.05%
PTCT - NAMS
41%
Loosely correlated
-0.99%
VKTX - NAMS
40%
Loosely correlated
-1.37%
ROIV - NAMS
40%
Loosely correlated
-1.47%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PVLA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PVLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-1.59%
PVLA - TRVI
40%
Loosely correlated
-0.38%
KURA - TRVI
37%
Loosely correlated
+1.54%
NAMS - TRVI
36%
Loosely correlated
+0.32%
PCVX - TRVI
36%
Loosely correlated
+2.09%
SYRE - TRVI
36%
Loosely correlated
-1.21%
More